Life after breast cancer has a clinical roadmap — most survivors never receive it. A gynecologist names the three care gaps survivors should close.

Recurrent breast cancer isn't one diagnosis — it's three. Local types aren't stage 4. CDK4/6 inhibitors now lead ER-positive distant recurrence treatment.

Stage 4 breast cancer treatment is now subtype-specific — T-DXd, CDK4/6 inhibitors, and PARP inhibitors matched to HER2, ER+, and BRCA status in 2026.

Dense breast tissue raises cancer risk 2.5x in BI-RADS D patients — and mammogram sensitivity can fall to 60–70% in dense tissue.

Egg freezing is clinically safe for ER+ breast cancer patients — a fact most premenopausal patients aren't told before their first oncology appointment.

Breast cancer during pregnancy carries a ~99% five-year survival rate at Stage I per 2026 NCI SEER data — but only when specialist care begins within 48 hours of diagnosis.

Male breast cancer's most dangerous symptom is painlessness. 75–80% of cases present with a painless lump men dismiss for 12+ months.

Black women with TNBC lose tamoxifen access. An oncologist explains 2026 NCCN screening age, BRCA testing, and pembrolizumab eligibility.

BRCA gene test positive means predisposition, not diagnosis — but for BRCA1 carriers, lifetime breast cancer risk reaches up to 72%.

Breast reconstruction after mastectomy means choosing between implants and DIEP flap — and radiation therapy changes which option is clinically safer.